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Abstract
Background: Data about the impact of chronic kidney disease (CKD) on health care costs in Spain are scarce This
study was aimed to evaluate cumulative costs and healthcare utilisation in CKD in Spain.
Methods: Observational, retrospective, population-based study, which included adults who received care for CKD
between 2015 and 2019. Healthcare and medication costs were summarized on a yearly basis starting from the
index date (1st January 2015), and then cumulatively until 2019.
Results: We identified 44,214 patients with CKD (year 2015: age 76.4 ± 14.3 years, 49.0% women, albumin-to-
creatinine ratio 362.9 ± 176.8 mg/g, estimated glomerular filtration rate 48.7 ± 13.2 mL/min/1.73 m2). During the
2015–2019 period, cumulative CKD associated costs reached 14,728.4 Euros, being cardiovascular disease
hospitalizations, particularly due to heart failure and CKD, responsible for 77.1% of costs. Total medication cost
accounted for 6.6% of the total cost. There was a progressive decrease in cardiovascular disease hospital costs per
year (from 2741.1 Euros in 2015 to 1.971.7 Euros in 2019). This also occurred with cardiovascular and diabetic
medication costs, as well as with the proportion of hospitalizations and mortality. Costs and healthcare resources
use were higher in the DAPA-CKD like population, but also decreased over time.
Conclusions: Between 2015 and 2019, costs of patients with CKD in Spain were high, with cardiovascular
hospitalizations as the key determinant. Medication costs were responsible for only a small proportion of total CKD
costs. Improving CKD management, particularly with the use of cardiovascular and renal protective medications
may be helpful to reduce CKD burden.
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Introduction
Chronic kidney disease (CKD) is a common condition
that affected nearly 700 million persons worldwide in
2017. However, these numbers are expected to rise due
to the ageing of the population, and the increasing
prevalence of hypertension and diabetes [1–3]. CKD
markedly increases the risk of developing cardiovascular
disease, particularly ischemic heart disease and heart
failure [HF], as well as cardiovascular and all-cause
death. In addition, CKD promotes the development of
end-stage renal disease [2, 4]. Remarkably, the risk of ad-
verse outcomes increases as renal function decreases or
albuminuria develops [5].
The apropriate treatment of CKD patients has been as-
sociated with a reduction in the risk of developing car-
diovascular and renal complications [6]. This is
particularly true with the use of renin angiotensin sys-
tem inhibitors, including angiotensin-converting enzyme
inhibitors (ACEi) and angiotensin-receptor blockers
(ARBs) [7, 8], and more recently, with the use of some
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sodium-glucose cotransporter-2 (SGLT-2) inhibitors [9,
10], even in the absence of type 2 diabetes (T2D) [9].
Of note, CKD represents a major and growing eco-
nomic problem [3, 11, 12]. Increasing the knowledge
about CKD-related costs is mandatory to ascertain how
CKD management can be improved, leading to a signifi-
cant decrease in CKD burden [5, 11–18]. Unfortunately,
data about the impact of CKD on health care costs in
Spain are scarce, and most importantly, not focused on a
comprehensive approach [19, 20].
The aim of this study was to evaluate the cumulative
costs and healthcare utilisation in CKD patients in Spain
over the last 5 years, along with the epidemiological
characterization of the population at index date (1st
January 2015). This was also analyzed in a population
who met the main inclusion criteria of the DAPA-CKD
trial [9] (DAPA-CKD like population).
Methods
This was an observational cohort study, comprising
cross-sectional and longitudinal retrospective analyses
using secondary data captured in electronic health re-
cords from seven Spanish regions, from the BIG-PAC®
database. BIG-PAC® database included information from
non-selected 1.7 million persons of primary health cen-
ters and referral hospitals within the Spanish national
health system. Before export to BIG-PAC®, data were
rigorously anonymized and dissociated, making not pos-
sible individual identification. As a result, it automatic-
ally collects information from routine practice, without
requiring manual inputting. Previous studies have dem-
onstrated its representativeness of the Spanish popula-
tion [21, 22].
This database has been validated as an information
source for studies of epidemiology, therapeutic adaptation
and health/non-healthcare resource use and associated
costs. It is representative of the Spanish population [21].
The study was approved by the Investigation Ethics Com-
mittee of Consorci Sanitari from Terrassa. Informed con-
sent was waived by the same ethics committee that
approved the study, as this was a secondary data study
and data were fully anonymized and dissociated from pa-
tients. All methods were performed in accordance with
the relevant guidelines and current regulations [21, 23].
The study population included all adult patients with
at least one diagnostic code of CKD or having laboratory
results meeting the definition of CKD prior to the index
date (1st January 2015). CKD stages 1–5 were defined
according to the estimated glomerular filtration rate
(eGFR; estimated by the CKD-Epidemiology Collabor-
ation equation) and the urine albumin-to-creatinine ra-
tio (UACR), as follows: stage 1: eGFR ≥90 mL/min/
1.73m2 and UACR ≥30mg/g; stage 2: eGFR 60–89mL/
min/1.73m2 and UACR ≥30mg/g; stage 3a: eGFR 45–59
mL/min/1.73m2; stage 3b: eGFR 30–44mL/min/1.73m2;
stage 4: eGFR 15–29 mL/min/1.73m2; stage 5: eGFR <
15mL/min/1.73m2 [23, 24]. T2D was defined as all adult
patients filling a prescription of any antidiabetic medica-
tion, having a T2D diagnostic code or HbA1c > 7% prior
to index date, excluding type 1 diabetes. The DAPA-
CKD like population included those adult patients, with
or without T2D, but not type 1 diabetes, who had an
eGFR of 25 to 75mL/min/1.73 m2 and a UACR of 200
to 5000 mg/g, on stable treatment with ACEi or ARBs
for at least 1 month [9].
Baseline characteristics for the overall CKD and
DAPA-CKD like populations, including demographics,
comorbidities and medications, were calculated at index
date (1st January 2015) for the full group and by T2D
status and CKD stage. The main comorbidities included
myocardial infarction (MI), HF, atrial fibrillation (AF),
stroke, peripheral artery disease (PAD), hyperkalemia
and diabetes. A minimum of 1-year of data before index
date was required. ICD-9 and ICD-10 codes (https://
eciemaps.mscbs.gob.es) were considered for the diagno-
sis of comorbidities (supplementary Table 1). Treat-
ments were recorded from the registries for dispensing
medicines, according to the Anatomical Therapeutic
Chemical Classification System (supplementary Table 1)
[25]. Treatment for hypertension/HF (ACEi, ARBs, dir-
ect renin inhibitors, aldosterone antagonists, angiotensin
receptor and neprilysin inhibition, beta blockers, di-
uretics, calcium channel blockers), antidiabetics (SGLT-
2 inhibitors, metformin, sulfonylureas, dipeptidyl peptid-
ase 4 [DPP-4] inhibitors, glucagon-like peptide-1 [GLP-
1] receptor agonists, meglitinides, glitazones, acarbose,
miglitol, insulin), antithrombotic therapy (warfarin, as-
pirin, P2Y12 receptor antagonists) and statins were re-
corded. Prescriptions were performed according to
physicians´ criteria in routine practice [23].
Prevalence and incidence of CKD were also calculated
at index date (1st January 2015). Incidence was calcu-
lated as all newly diagnosed patients during 2015 divided
by the number of patients without CKD in the popula-
tion at the beginning of 2015 and expressed in cases per
1000 patient-years. Prevalence was calculated as all pa-
tients with a CKD diagnosis at the end of 2015, divided
by all individuals in the total population covered by the
database at that time. The denominator included all in-
dividuals that were attended by any reason in the Span-
ish health care system in the previous 3 years to the
index date (2012–2014). Mortality data were updated
every month in the BIG-PAC database.
Costs were not taken from BIG-PAC database. Data
were calculated using sources from the Spanish National
Healthcare System of 2019 (supplementary Table 2) and
used for the overall study period [21]. The healthcare re-
source use and costs and medication and procedure
Escobar et al. BMC Health Services Research          (2021) 21:536 Page 2 of 14
costs were summarized on a yearly basis starting from
index date (1st January 2015), and then cumulatively
until the end of the last year of follow-up (31st Decem-
ber 2019). All hospital visits (total and cardiovascular
events), medical and emergency room visits, medication
costs, and procedure costs (total, dialysis, kidney trans-
plant) were included for the analysis of the annual direct
healthcare costs [21]. Costs per patient were calculated
every year. Patients who died during the follow-up had a
cost of 0 allocated to the remaining duration of the
study, whereas a patient leaving the database prior to
data cut off was not included in the denominator for the
time after leaving the database. No double counting oc-
curred, as for each cost (i.e CKD hospitalizations) only
that category was counted.
Annual indirect non-health costs included the number
of days of productivity lost due to disability [21]. Rates
were obtained from hospital accounting, except for
medication and indirect costs, which were calculated as
follows, respectively: a) medical prescriptions: according
to the retail price per package at the time of dispensing
[26]; b) costs for days of productivity lost: according to
the mean interprofessional wage. The estimation of days
off of work were obtained by the temporary work incap-
acity reported in primary care setting [27]. Hospital ad-
mission costs of cardiovascular events during follow-up
were obtained taking into consideration the daily hos-
pital rate and the number of hospital days per stay.
Statistical analysis
Categorical variables were described by their absolute
(n) and relative frequencies (%) and continuous variables
by the mean and standard deviation. Categorical vari-
ables were compared with the Chi-square test and
means by the t-student test. Analyses of health care cost
were performed for the index date with 5 year of follow-
up. The cumulative mean healthcare cost was estimated
and presented on a yearly basis from the index date until
last year of follow-up. Health care costs were presented
per patient (mean cost). A level of statistical significance
of 0.05 was applied in all the statistical tests. The data
were analyzed using the statistical package SPSS v22.0
(SPSS Inc., Chicago, Illinois, USA) [21].
Results
Out of 1,7 million people included in the BIG-PAC®
database in 2015, 1,3 were attended during the 2012–
2014 period, of whom 964,862 were 18 years or older. At
index date, 45.376 patients had CKD. As 1162 patients
were excluded due to inconsistent data, 44,214 patients
(97.4%) comprised the CKD study population (Fig. 1).
Incidence at index date was 2.06 per 1000 patient-years
and the prevalence was 4.90%.
The baseline clinical characteristics of the CKD popu-
lation according to the presence of T2D and CKD stage
are presented in Table 1. Overall, mean age was 76.4 ±
14.3 years, 49.0% of patients were women, mean UACR
was 362.9 ± 176.8 mg/g and mean eGFR 48.7 ± 13.2 mL/
min/1.73 m2. Overall, 20.0% of patients had a history of
HF, 15.3% MI, and 10.5% stroke. With regard to treat-
ments, 71.0% were taking renin angiotensin system
(RAAS) inhibitors, but only 4.4% of patients at maximal
doses. A total of 19,985 (45.2%) patients had T2D. Pa-
tients with T2D were younger (75.8 ± 14.0 vs 76.4 ± 14.1
years; P = 0.001), but UACR (391.3 ± 189.4 vs 347.4 ±
172.3 mg/g, P < 0.001), and HbA1c (7.7 ± 2.0 vs 6.2 ±
1.2%; P < 0.001) were higher and eGFR lower (47.5 ± 12.4
vs 49.6 ± 11.3 mL/min/1.73 m2, P < 0.001) compared to
those without T2D. Moreover, comorbidities were more
Fig. 1 Flowchart costs population (2015). CKD: chronic
kidney disease
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common among patients with T2D. In addition, more
T2D patients were taking RAAS inhibitors (82.2% vs
61.7%; P < 0.001). Overall, 71.0% of patients had stage ≥3
CKD. Age increased as renal function worsened (from
69.8 ± 14.7 years in patients with stage 1 CKD to 79.8 ±
14.6 years among stage 5 CKD patients; P < 0.001), as
well as UACR (from 106.8 ± 49.8 mg/g to 1642.3 ± 769.2
mg/g; P < 0.001) and the proportion of patients treated
with RAAS inhibitors (from 66.5 to 72.6%; P < 0.001).
Similarly, comorbidities increased as renal function de-
creased (Table 1).
Patient hospital mean costs per year are presented in
Table 2. From 2015 to 2019 there was a progressive de-
crease in cardiovascular disease hospital cost per patient
year (from 2741.1 to 1971.7 Euros) and patient cumula-
tive cardiovascular disease hospital mean cost reached
11,349.2 Euros in 2019 (supplementary Table 3 and
Fig. 2a). The great burden of hospital cost was due to
cardiovascular hospitalizations, particularly HF and
CKD. Regarding medications, from 2015 to 2019, dia-
betes drugs mean cost decreased from 102.71 to 89.99
Euros per patient and year, but HF medication mean
cost slightly increased from 50.68 to 53.04 Euros, re-
spectively (Table 2). The cumulative mean cost of dia-
betes and HF medications reached 503.9 and 220.6
Euros, respectively, in 2019 (supplementary Table 3 and
Fig. 2b). Dialysis cost decreased from 2328.8 to 1624.2
Euros, respectively (cumulative cost of 9602.9 Euros)
and kidney transplant from 655.7 to 465.2 Euros, re-
spectively (cumulative cost of 2701.8 Euros) (supplemen-
tary Table 3 and Fig. 2c).
The health resources use for each year is shown in
Table 3. The proportion of hospitalized patients de-
creased from 27.6% in 2015 to 21.2% in 2019; P < 0.001,
the days for hospitalized patients from 16.4 to 11.2 days;
P < 0.001, and the proportion of patients that died from
8.7 to 4.3%; P < 0.001, respectively. Total health-related
cost decreased from 3561 Euros in 2015 to 2493 Euros
in 2019. Including indirect costs, total cumulative patient
mean costs reached 14,728.4 Euros in 2019; 651,203,
550.3 Euros per total CKD population (Table 4).
A specific analysis was performed in the DAPA-CKD
like population (n = 5925). In this group of patients,
mean age was 76.5 ± 14.6 years, 48.5% were women, and
mean UACR was 420.7 ± 198.8 mg/g. Overall, 20.8% of
patients had a history of HF, 13.4% MI, and 10.8% prior
stroke. With regard to treatments, all patients were tak-
ing RAAS, but only 13.4% of patients at maximal doses.
A total of 2951 (49.8%) patients had T2D. Patients with
T2D had higher UACR (426.3 ± 201.5 vs 350.2 ± 171.4
mg/g; P < 0.001), and HbA1c (7.5 ± 2.0 vs 5.8 ± 1.3%;
P < 0.001), but without significant differences in eGFR
(49.5 ± 12.0 vs 50.0 ± 11.8 mL/min/1.73 m2; P = 0.336).
In addition, comorbidities were more common among
patients with T2D compared to those without T2D.
Overall, in the DAPA-CKD like population, 95.2% had
Table 2 Patients hospital mean cost per yeara
2015 2016 2017 2018 2019 Cumulative
cost in
2019
mean SD mean SD mean SD mean SD mean SD
Total hospital cost
CVD 2741.1 5097.5 2452.6 5049.5 2308.3 5001.4 1875.5 4953.3 1971.7 4953.3 11,349.2
Cardiorenal 2500.3 4924.3 2250.7 4654.3 2105.9 4180.7 1685.4 3412.9 1766.7 3935.4 10,309.0
HF 1514.3 3602.4 1341.9 3160.5 1283.9 3023.9 1115.0 2520.9 1012.6 2426.7 6267.7
CKD 986.0 4.044.9 908.7 4026.2 822.0 3860.2 570.4 2866.6 754.2 3410.9 4041.3
MI 74.3 732.7 61.6 589.2 55.0 516.1 55.3 560.2 65.4 596.4 311.5
Stroke 111.7 784.8 99.4 754.1 105.4 792.1 94.6 732.0 99.8 749.0 510.9
PAD 54.9 658.9 41.0 506.8 42.0 544.6 40.2 521.5 39.7 551.9 217.8
Medication cost
Total medication 181.80 384.70 178.83 382.2 180.97 352.0 142.66 249.7 167.76 323.0 852.0
Diabetes medication 102.71 341.10 99.81 348.0 128.51 443.6 82.84 291.7 89.99 291.5 503.9
HF medication 50.68 76.76 47.34 72.4 31.88 53.2 37.71 60.4 53.04 93.4 220.6
CVD medication 28.41 62.40 31.68 71.7 20.58 46.1 22.11 45.6 24.73 53.0 127.5
Procedure costs
Total procedures 2984.5 23,547.4 2657.5 21,616.1 2516.5 20,106.6 2056.8 15,954.3 2089.4 16,415.2 12,304.7
Dialysis 2328.8 22,021.0 2081.3 19,672.1 1965.2 18,523.3 1603.4 15,265.7 1624.2 15,465.8 9602.9
Kidney transplant 655.7 4720.9 576.2 4026.3 551.3 3898.3 453.4 3.267.1 465.2 3402.9 2701.8
CVD cardiovascular disease, HF heart failure, CKD chronic kidney disease, MI myocardial infarction, PAD peripheral artery disease
aIn Euros. Cardiorenal disease includes HF and CKD
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stage 3 or 4 CKD. UACR increased as renal function
worsened (from 127.9 ± 58.5 in patients with stage 2
CKD to 1689.3 ± 841.3 mg/g among stage 4 CKD pa-
tients; P < 0.001), as well as comorbidities. In addition,
the proportion of patients at maximal doses of ACEi or
ARBs also increased as stage CKD worsened (from
10.3% in patients with stage 2 CKD to 17.2% among
stage 4 CKD patients; P < 0.001) (supplementary
Table 4).
With regard to patients hospital mean cost per year in
the DAPA-CKD like population, there was a progressive
decrease in cardiovascular disease hospital cost per year
(from 3025.9 Euros in 2015 to 2022.9 Euros in 2019).
Overall, patient cumulative cardiovascular disease hos-
pital mean cost reached 12,219.0 Euros in 2019. The
great burden of this cost was due to cardiovascular
hospitalizations, particularly HF and CKD. Regarding
medications, from 2015 to 2019, diabetes drugs mean
cost decreased from 103.7 to 99.0 Euros and HF medica-
tion mean cost from 57.8 to 53.0 Euros, respectively.
The cumulative mean cost of diabetes and HF medica-
tions reached 560.2 and 242.8 Euros, respectively, in
2019. Dialysis cost decreased from 2282.2 to 1591.7
Euros, respectively (cumulative cost of 9501.3 Euros)
and kidney transplant from 727.8 to 502.4 Euros, re-
spectively (cumulative cost of 2973.4 Euros) (supplemen-
tary Table 5).
Discussion
Our data showed that in Spain, during the 2015–2019
period, CKD-associated costs were substantial, being
cardiovascular hospitalizations the most important con-
tributing factor (77.1%), mainly HF and CKD hospitali-
zations; however, medication cost contribution was
marginal (6.6%). Of note, the annual cardiovascular
hospitalization mean cost and mortality progressively de-
creased over time.
In our study, the prevalence of CKD was nearly 5%
(mean age 76 years; 71% stage ≥3 CKD). Previously per-
formed studies in Spain have shown a higher prevalence
of CKD, possibly due to differences in the inclusion cri-
teria, the methods for renal function determination and
the study design. Since this is database study, patients
with CKD risk factors (such as diabetes mellitus, hyper-
tension or cardiovascular disease, who are not regularly
screened and therefore identified) cannot be reflected,
showing the high underdiagnosis rate of CKD still
present nowadays. Additionally, this difference in CKD
prevalence might be a consequence of a higher use of
CKD protective treatments [23, 28–30]. Despite the fact
that 71% of patients were taking RAAS inhibitors (82%
among T2D patients) in our study, only 4.4% of patients
reached maximal doses, suggesting that there is still a
potential benefit on CKD outcomes with uptitration). It
is likely that the risk of hyperkalemia or renal function
impairment associated with these drugs, mainly in eld-
erly patients or in advanced CKD could have had some
impact on these results [31]. However, these numbers
were not significantly higher in stage 1–2 CKD patients.
As it has been reported that achieving maximal doses of
RAAS inhibitors (vs lower doses) may be associated with
better outcomes, it is highly recommended the use of
cardiovascular and renal protective drugs at adequate
doses to reduce outcomes [32, 33]. The reduction in the
proportion of hospitalized patients, days of
hospitalization and mortality during the 2015–2019
period could be related with a better comprehensive
management of CKD population, including the use of
guidelines recommended drugs [33–36].
Fig. 2 Patient cumulative hospital (A), medication (B) and
procedures (C) mean costs*. *In Euros. CVD: cardiovascular disease;
HF: heart failure; CKD: chronic kidney disease; MI: myocardial
infarction; PAD: peripheral artery disease. Cardiorenal costs include
HF and CKD costs
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2 1636 (3.7) 1680 (3.8) 0.434 1724 (3.9) 0.12 1769 (4.0) 0.02 1724 (3.9) 0.12 5261 (11.9)
3+ 265 (0.6) 133 (0.3) <
0.001
221 (0.5) 0.044 265 (0.6) 0.999 309 (0.7) 0.064 6862 (15.5)
Disability
Days of disability 0.3 4.2 0.3 4.5 – 0.4 5.6 0.003 0.4 5.9 0.004 0.4 5.9 0.004 1.9 17.5
Average days of sick leave
(disability only)









Patients with disability, n (%) 354 (0.8) 354 (0.8) – 398 (0.9) 0.105 442 (1.0) 0.002 398 (0.9) 0.105 1326 (3.0)










Patients alive at the end of the
year, n
40,367 37,360 – 34,928 – 32,762 – 30,861 – –
Table 4 Total mean cost for year and cumulative cost in 2019a per patient
2015 2016 2017 2018 2019 Cumulative
cost in
2019
mean SD mean SD mean SD mean SD mean SD
Primary care visits 300.1 358.2 256.5 297.7 222.6 251.7 203.3 232.3 181.5 200.9 1164.0
Laboratory requests 25.8 38.8 22.6 48.5 22.6 48.5 19.4 45.2 19.4 42.0 109.8
Radiology and other tests 17.1 37.1 17.1 37.1 17.1 39.9 20.0 42.8 20.0 42.8 91.2
Specialized visits 179.6 387.5 104.0 406.4 94.5 396.9 85.1 387.5 66.2 368.6 529.2
Emergency room visits 83.0 272.6 71.1 308.1 59.3 248.9 59.3 248.9 47.4 225.2 320.0
Hospitalization 2741.1 5097.5 2452.6 5049.5 2308.3 5001.4 1875.5 4.953.3 1971.7 4.953.3 11,349.2
Medication 214.1 421.4 198.7 415.6 185.3 413.5 184.3 421.4 186.8 443.6 969.2
Health-related cost 3561 5492 3123 5276 2910 5128 2447 4516 2493 4628 14.532.6
Indirect Cost/Sick Leave 33 423 34 455 41 564 45 593 42 599 195.8
Total Cost 3594 5915 3157 5731 2951 5691 2491 5109 2535 5227 14,728.4
aIn Euros
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More recently, the CREDENCE and DAPA-CKD trials
have shown that among CKD patients with T2D, the use
of SGLT-2 inhibitors translates into better cardiovascu-
lar and renal outcomes [9, 10]. In addition, the DAPA-
CKD and the DECLARE-TIMI 58 trials have demon-
strated that the beneficial effect of dapagliflozin on the
development of cardiovascular and renal complications
can be extended to the CKD population without T2D,
and to T2D individuals with normal renal function at
baseline, respectively [9, 34]. These data suggest that the
addition of these drugs to the treatment of CKD patients
could reduce even more morbidity and mortality, and
consequently, overall CKD burden.
Our study showed that total cumulative cost of CKD
patients was high. This has also been confirmed by pre-
vious studies [11–18]. The most important contributors
for total health care cost in CKD patients were cardio-
vascular hospitalizations (admissions and hospital stay),
particularly HF and CKD hospitalizations. This is not
surprising, as CKD is associated with an increased risk
of cardiovascular death, and progression to end-stage
renal disease [37, 38]. There is a close relationship be-
tween CKD and HF. Thus, the presence of one condition
promotes the development of the other, and vice versa
[39]. In fact, HF can be an early complication of CKD.
This has also been observed in the overall T2D popula-
tion [39]. In the last years, a number of clinical trials
have demonstrated the marked benefits of treatment
with SGLT-2 inhibitors in the reduction of HF hospitali-
zations among T2D population [40]. Similarly, SGLT-2
inhibitors substantially decrease kidney composite out-
comes in patients with T2D [41]. Unfortunately, in our
study, only 2% of patients with T2D were taking SGLT-2
inhibitors at index date since this was 2015 and SGLT-2
inhibitors had been recently launched. It is very likely
that the higher use of these drugs in T2D and non T2D
populations will translate into a reduction of cardiovas-
cular and renal complications and secondarily to a de-
crease of health care related costs [42, 43].
Different studies have shown that health care costs in-
crease as renal function worsens or albuminuria de-
velops, particularly in patients that finally require kidney
replacement therapy [5, 11–14, 16, 20, 44–46]. As a re-
sult, although renal replacement therapy has been the
object of constant analysis in order to improve the effi-
ciency and sustainability, the fact is that preventing the
occurrence and progression of CKD is the best way to
reduce health care resource consumption and health
care costs. Therefore, interventions designed to
minimize decline in progressive kidney function, particu-
larly among patients with stage 3 or 4 CKD, may reduce
the economic CKD burden [5, 11–14, 16, 20, 44–47]. It
has been reported that the addition of RAAS inhibitors
to prevent the advance of nephropathy is worthwhile not
only from a clinical perspective, but also from an eco-
nomic point of view, even in patients with end stage
renal disease, mainly driven by a reduction of
hospitalization costs [47, 48]. Both, the CREDENCE and
the DAPA-CKD trials showed that among CKD patients,
the use of SGLT-2 inhibitors could prevent or delay the
development of kidney complications, including end-
stage renal disease [9, 10]. Our data showed a progres-
sive reduction of costs associated with dialysis and kid-
ney transplant. Although this is hopeful, a higher use of
renal protective drugs, including RAAS inhibitors and
SGLT-2 inhibitors with proven renal benefit, could pro-
vide additional benefits, including health care costs
reduction.
Other contributors to total CKD cost included primary
care visits, specialized visits, and diagnostic tests. It has
been reported that not only the costs of specialized care
decrease with the length of hospital stay reduction [19],
but also a nephrologist/nurse-based multifaceted inter-
vention for stage 3 to 4 CKD patients may be a cost ef-
fective approach [49], suggesting that an integrated
management of CKD patients in both specialist and pri-
mary care settings is warranted to reduce CKD burden.
In our study, cardiovascular outcomes were more
common in the DAPA-CKD like subpopulation than in
the general CKD population [23], translating into higher
costs. This has been confirmed in a real-world popula-
tion similar to that of DAPA-CKD [50]. Despite the
beneficial effects shown in the DAPA-CKD trial with
dapagliflozin on the prevention of cardiovascular and
renal outcomes in CKD patients, regardless the presence
of T2D [9], in our study, less than 4% of T2D patients
from the DAPA-CKD like subpopulation were taking
SGLT-2 inhibitors [50]. As a result, it would be desirable
a higher use of these drugs in this population with the
double aim of decreasing outcomes and health care
costs.
Limitations
As this study had a retrospective design, only indirect
causality may be suggested. In addition, some relevant
data, such as albuminuria could not be documented in
all patients, leading to an underdiagnosis of CKD. How-
ever, this is the best design to ascertain the therapeutic
management of patients and health care costs in clinical
practice, as no specific intervention was required to be
included. Furthermore, the high number of patients in-
cluded, as well as the robustness of the data allow
achieving the objectives of the study. Unfortunately,
medications were only recorded at baseline and no dir-
ect association can be determined between the decrease
of events and costs and the use of cardiovascular medi-
cations. On the other hand, patients without a CKD
diagnosis who met the definition of CKD stage 1 or
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higher were also considered as CKD patients and se-
lected for the study. Although multiple readings of the
eGFR are required to define CKD, due to the character-
istics of the study, only one measurement was consid-
ered. However, the later represented only 6.9% of the
total CKD study population and it was not expected that
this had a significant impact on the results. Costs were
taken from the Spanish National Healthcare System of
2019 and used for the overall study period. Although
this could be a limitation, changes in costs during this
time were marginal. In addition, improvements in effi-
ciencies in hospital process may also reduce costs. Un-
fortunately, this could not be determined. Finally,
although data came from seven Spanish regions, previ-
ous studies have shown that these data are representa-
tive of the entire Spanish population [21].
Conclusions
During the period 2015–2019, costs of patients with
CKD in Spain were substantial, with cardiovascular hos-
pitalizations being the key determinant, particularly in
HF with CKD. Medication costs were responsible for
only a small proportion of total CKD costs. Costs and
healthcare resources use were even higher in the DAPA-
CKD like population. Improving CKD management, par-
ticularly with the use of cardiovascular and renal pro-
tective medications may be helpful to reduce CKD
burden.
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